JMT106 / CSPC Pharma - LARVOL DELTA

A Study of JMT106 Injection in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P1 trial • Hepatocellular Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (HKEXnews) - "The board of directors (the 'Board') of CSPC Pharmaceutical Group Limited (the 'Company', together with its subsidiaries, the 'Group') is pleased to announce that JMT106 (the 'Product'), a bispecific fusion protein drug developed by the Group, has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. The Product was also approved by the U.S. Food and Drug Administration (FDA) in January 2024 to conduct clinical trials in the U.S. The indication for this clinical trial approval is advanced solid tumors."

New trial • Solid Tumor